ARVAX advances a focused portfolio of longevity programs targeting the biological hallmarks of aging — cellular energy, inflammation, and neuroprotection.
Each program follows our translational model: rigorous biomarker strategy, rapid ANZ initiation under CTN/CTX, and globally credible human data.
Each program follows our translational model: rigorous biomarker strategy, rapid ANZ initiation under CTN/CTX, and globally credible human data.
- AV-1959R — Alzheimer’s Prevention VaccineA next-generation active immunotherapy designed to prevent or delay Alzheimer’s disease by inducing a targeted immune response against amyloid-beta.
Status: Phase 1 clinical study underway at CMAX (Adelaide, Australia).
Objectives: Safety, dose response, and immunogenicity, with exploratory neuroinflammatory biomarkers.
Goal: To establish early proof of mechanism for a scalable, preventive approach to neurodegeneration
- MitoRegen-1 — Mitochondrial Bio-Resilience ModulatorAn oral small molecule aimed at restoring mitochondrial efficiency and cellular energy balance associated with aging, fatigue, and muscle decline.
Status: Pre-IND; IND-enabling toxicology and formulation studies ongoing (2025).
Planned FIH: 2026 (Australia).
Goal: Demonstrate safety, PK/PD correlation, and bioenergetic biomarker modulation in early human studies.
- Senolyze-X — Selective Senotherapeutic Peptide ComplexA proprietary peptide complex that selectively clears senescent cells through BCL-xL degradation and FOXO4-p53 pathway modulation.
Status: IND targeted for mid-2026; first-in-human study expected late 2026 (ANZ).
Goal: Establish tolerability and biomarker shifts in metabolic and frailty-related endpoints.
Pipeline Expansion
ARVAX continuously sources and evaluates early-stage longevity assets through partnerships with academic centers, biotech founders, and R&D institutions.
Our focus includes vaccines, small molecules, and peptide therapeutics addressing inflammation, mitochondrial function, and neurodegeneration.
Partner with us to explore how your discovery can become a first-in-human program within the ARVAX ecosystem.
Our focus includes vaccines, small molecules, and peptide therapeutics addressing inflammation, mitochondrial function, and neurodegeneration.
Partner with us to explore how your discovery can become a first-in-human program within the ARVAX ecosystem.
MENU
CONTACTS
Legal Disclaimer
The information provided on this website is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or investment product. Nothing contained on this site should be interpreted as investment, legal, tax, or other professional advice, and visitors should not rely solely on the information presented herein for making investment or other decisions.
Investments in early-stage biotechnology, vaccines, and preventive medicine companies involve a high degree of risk, including the potential loss of invested capital. Past performance is not indicative of future results, and there can be no assurance that any investment strategy will achieve its objectives.
Any references to portfolio companies, strategic partners, or case studies are provided solely for illustrative purposes and should not be construed as a guarantee of future investment opportunities or performance. Forward-looking statements, projections, or expectations expressed on this site are inherently uncertain and subject to change without notice.
Access to certain investment opportunities is restricted to qualified or accredited investors as defined under applicable securities laws. Visitors should consult with their own legal, financial, and tax advisors before making any investment decisions.
By using this website, you acknowledge and agree that Arvax shall not be liable for any losses or damages arising from reliance on the information contained herein.
This website and its contents are governed by and construed in accordance with the laws of the United Arab Emirates (UAE). Any disputes arising out of or related to the use of this website shall be subject to the exclusive jurisdiction of the courts of the United Arab Emirates.
The information provided on this website is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or investment product. Nothing contained on this site should be interpreted as investment, legal, tax, or other professional advice, and visitors should not rely solely on the information presented herein for making investment or other decisions.
Investments in early-stage biotechnology, vaccines, and preventive medicine companies involve a high degree of risk, including the potential loss of invested capital. Past performance is not indicative of future results, and there can be no assurance that any investment strategy will achieve its objectives.
Any references to portfolio companies, strategic partners, or case studies are provided solely for illustrative purposes and should not be construed as a guarantee of future investment opportunities or performance. Forward-looking statements, projections, or expectations expressed on this site are inherently uncertain and subject to change without notice.
Access to certain investment opportunities is restricted to qualified or accredited investors as defined under applicable securities laws. Visitors should consult with their own legal, financial, and tax advisors before making any investment decisions.
By using this website, you acknowledge and agree that Arvax shall not be liable for any losses or damages arising from reliance on the information contained herein.
This website and its contents are governed by and construed in accordance with the laws of the United Arab Emirates (UAE). Any disputes arising out of or related to the use of this website shall be subject to the exclusive jurisdiction of the courts of the United Arab Emirates.
